Fresenius
Fresenius SE & Co. KGaA is a German global healthcare group operating Fresenius Kabi (biopharmaceuticals, biosimilars, IV generics, clinical nutrition, and medical devices) and Fresenius Helios (Europe's largest private hospital network in Germany and Spain), serving approximately 27 million patients annually with FY2025 revenue of €22.5–22.6 billion.
- Company typePublic
- Founded1912
- HeadquartersBad Homburg Vor Der Höhe, Germany
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingServices
What Fresenius does
Fresenius SE & Co. KGaA is a German global healthcare group founded in 1912 and headquartered in Bad Homburg vor der Höhe, listed on the Frankfurt Stock Exchange and a DAX index constituent. Following the May 2026 deconsolidation of Fresenius Medical Care (now treated as a financial investment), the group operates through two main businesses: Fresenius Kabi, which supplies biopharmaceuticals, biosimilars (Conexxence, Bomyntra, Otulfi), IV generics, clinical nutrition (Fresubin, Pedismof), infusion and transfusion technologies, and cell processing systems (Lovo and Cue) to hospitals and healthcare providers globally; and Fresenius Helios, which operates Europe's leading private hospital network with roughly 140 clinics — Helios Kliniken in Germany (80+ hospitals, ~200 outpatient centers) and Quirónsalud in Spain (57 hospitals) — serving approximately 27 million patients annually. The group reported €22.5–22.6 billion in FY2025 revenue with about 178,000 employees (excluding Fresenius Medical Care), and is executing its #FutureFresenius REJUVENATE strategy across three therapy platforms: (Bio)Pharma including clinical nutrition, MedTech, and Care Provision.
Fresenius generates revenue primarily through B2B direct sales of pharmaceutical products, infusion systems, biosimilars, and medical devices to hospitals and healthcare providers worldwide via Fresenius Kabi's enterprise field sales force, complemented by Fresenius Helios's inpatient and outpatient hospital services revenue from German and Spanish operations (Helios Germany at €8.1B and Quirónsalud above €5.4B in 2025). Pricing is contract-driven and not publicly disclosed, with reimbursement for hospital services flowing through national and private healthcare payors. The company is investing heavily in digital infrastructure, including a strategic partnership with SAP and an investment in Avelios Medical to build a sovereign, interoperable AI-enabled hospital information system, alongside an AI/digital-twin biomanufacturing platform with HP at mAbxience, a U.S. epinephrine supply chain with Phlow Corp., and cell therapy partnerships with TQ Therapeutics and the EASYGEN consortium.
The company's competitive position rests on regulatory approvals (FDA interchangeability designation for denosumab biosimilars, EU approvals, FDA 510(k) clearances), a broad proprietary product portfolio across biosimilars, IV generics, and clinical nutrition, and the largest private hospital footprint in Europe. Strategic risk factors include European reimbursement pressure on hospital operations, dependency on German and Spanish regulatory regimes for the majority of Helios revenue, execution risk on multi-year digital and AI partnerships, and competitive intensity in biosimilars. The Else Kröner-Fresenius Foundation holds a significant ownership stake, providing stability, and CEO Michael Sen's contract has been extended through 2031 to lead the post-Fresenius Medical Care focused strategy.
Fresenius firmographics
Firmographics- Name
- Fresenius
- Legal name
- Fresenius SE & Co. KGaA
- Website
- https://fresenius.com
- Company type
- Public
- Founded year
- 1912
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Fresenius SE & Co. KGaA is a German global healthcare group operating Fresenius Kabi (biopharmaceuticals, biosimilars, IV generics, clinical nutrition, and medical devices) and Fresenius Helios (Europe's largest private hospital network in Germany and Spain), serving approximately 27 million patients annually with FY2025 revenue of €22.5–22.6 billion.
- Ownership category
- akta.pro rank
Fresenius industry classification
Industry- Product category
- Healthcare Services and Pharmaceutical Products
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), General Medical and Surgical Hospitals (622110)
- SIC
- Pharmaceutical Preparations (2834), Services-Hospitals (8060), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Fresenius is headquartered
LocationHeadquarters
- HQ city
- Bad Homburg Vor Der Höhe
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Fresenius business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Fresenius Kabi - Pharmaceutical and Medical Products: Sales of biopharmaceuticals, clinical nutrition products, IV generic drugs, medical technologies, and infusion systems. Fresenius Kabi reported sales of more than €8.5 billion in 2025.
- Fresenius Helios - Hospital Operations: Revenue from hospital operations in Germany and Spain. Helios Germany generated €8.1 billion in sales in 2025. Quirónsalud generated more than €5.4 billion in sales in 2025.
- Strategic Investments: Investment in Avelios Medical for next-generation hospital information systems as part of partnership with SAP for digital healthcare ecosystem.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Fresenius product offering
Product offeringCore offering
Fresenius is a global healthcare group selling pharmaceutical and medical products through Fresenius Kabi (biopharmaceuticals, biosimilars, clinical nutrition such as Fresubin and Pedismof, IV generics, infusion and transfusion systems including Aurora plasmapheresis and Cue/Lovo cell processing systems) to hospitals and healthcare providers worldwide. Through Fresenius Helios, it operates Europe's leading private hospital network with 140+ clinics across Germany (Helios Kliniken) and Spain (Quirónsalud), serving approximately 27 million patients annually.
Product overview
Fresenius is a diversified healthcare company with three main operating units: Fresenius Kabi (products for chronically and critically ill patients), Fresenius Helios (Europe's leading private hospital operator), and Fresenius Medical Care (now treated as a financial investment after deconsolidation). Fresenius Kabi's portfolio includes biopharmaceuticals/biosimilars (Conexxence, Bomyntra, Otulfi), clinical nutrition (Fresubin, Pedismof), infusion therapy products, transfusion technology (Aurora plasmapheresis systems, Cue and Lovo cell processing systems), and I.V. generic drugs. Fresenius Helios operates hospitals through Helios Kliniken in Germany and Quirónsalud in Spain/Latin America, serving approximately 27 million patients annually. The company's strategy focuses on three therapy platforms: (Bio)Pharma including clinical nutrition, MedTech, and Care Provision. Strategic partnerships with SAP for AI-enabled healthcare platforms and HP for biopharmaceutical manufacturing support digital transformation initiatives.
Differentiator
Problem solved
Functional benefit
Brands
- Fresenius Kabi: Global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, including biosimilars and IV generic drugs.
- Fresenius Helios
- Quirónsalud
- Helios Kliniken
- mAbxience
- Fresubin
- Conexxence (denosumab)
- Bomyntra (denosumab)
Products and services
- Fresenius Kabi Biopharmaceuticals and Biosimilars
- Fresenius Kabi Clinical Nutrition Products (Fresubin range)
- Pedismof parenteral nutrition range
- Fresenius Kabi Infusion Therapy Products
- Fresenius Kabi Transfusion Technology and Cell Therapy Devices (Aurora plasmapheresis systems, Cue and Lovo cell processing systems)
- Epinephrine Injection, USP
- Calcitonin Salmon Injection, USP Synthetic
- Fresenius Helios Hospital Operations (Helios Kliniken Germany and Quirónsalud Spain/Latin America)
Quantifiable outcome
- Approximately 27 million people served annually through Helios hospitals
- +2 more outcomes
Companies that use Fresenius
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Fresenius technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability7 records
Feature5 records
Fresenius partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Phlow Corp.minorFresenius Kabi entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP. Phlow produces U.S.-based API while Fresenius Kabi manufactures finished doses for hospitals and clinics across the country.
- SAP SEcoreSAP and Fresenius announced a strategic partnership to build a sovereign, interoperable, AI-supported healthcare platform. The companies plan to jointly invest a mid three-digit million euro amount in the medium term to drive digital transformation of the German and European healthcare system. The platform enables hospitals worldwide to use AI securely while meeting requirements for data sovereignty, security, and regulatory compliance.
- TQ TherapeuticsminorFresenius entered into a strategic development agreement with TQ Therapeutics to support scalable and efficient manufacturing of cell and gene therapies. Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics' proprietary cell selection technology into its Cue Cell Processing System.
- EASYGEN ConsortiumminorA European consortium called EASYGEN launched to develop an automated, modular point-of-care manufacturing platform for CAR T-cell cancer therapy, backed by €8 million in EU funding. The consortium brings together 18 academic, research, industry, and clinic partners across eight countries including Fresenius.
- CapgeminiminorFresenius Digital Technology partnered with Capgemini to implement a virtual agent called FreDi, integrating ServiceNow and Microsoft Teams to improve IT support delivery without adding external technology stacks to FDT's existing ecosystem.
Scale indicators8 records
Recent moves9 records
Expansion highlights7 records
Fresenius competitors and assessment
Company assessmentBroad incumbents
- DaVita: U.S.-based dialysis services giant and primary dialysis peer to Fresenius Medical Care. Relevant as a reference for the deconsolidated FMC investment exposure and to size the dialysis segment Fresenius has spun out.
- Siemens Healthineers: German healthcare technology giant with hospital imaging, diagnostics, and digital health offerings. Comparable for hospital technology/MedTech adjacency and European hospital customer base.
- Pfizer: Global pharmaceutical major with a substantial biosimilars portfolio and injectable pharmaceuticals business. Comparable to Fresenius Kabi for portfolio breadth and biosimilar pipeline depth.
- Quirónsalud (Fresenius subsidiary) vs. peer hospital operators: Ramsay Health Care is a global private hospital operator with significant European (UK, France, Scandinavia) operations, making it broadly comparable to Fresenius Helios for private hospital economics, M&A, and regulatory exposure.
- HCA Healthcare: Largest U.S. for-profit hospital operator, comparable to Fresenius Helios for private hospital economics, scale, and capital allocation profile — relevant for sizing hospital segment valuation.
Direct peers
- Baxter International: Baxter is a direct competitor to Fresenius Kabi in IV solutions, clinical nutrition, infusion pumps, and injectable pharmaceuticals, with overlapping global hospital distribution. Most comparable peer for the Kabi segment.
- Sandoz Group: Spin-off from Novartis focused on generics and biosimilars. Direct competitor in biosimilars (denosumab, ustekinumab overlap) and IV injectables; most focused biosimilars comparable to Kabi.
- ICU Medical: U.S.-based manufacturer of IV medical devices, infusion pumps, and connection systems directly competing with Kabi's infusion therapy portfolio. Strongly comparable for the MedTech segment.
- B. Braun Melsungen: German family-owned medical device and pharmaceutical company directly competing with Fresenius Kabi in IV fluids, infusion therapy, clinical nutrition, and surgical products across Europe and globally.
Emerging players
- Formycon: German biosimilars developer partnering with Fresenius Kabi on Otulfi (ustekinumab). Comparable for biosimilar development capabilities and emerging-market biosimilar positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Fresenius social profiles
Digital presenceFresenius compliance and trust
Trust signalCompliance4 records
Fresenius financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fresenius leadership team
Management profileNumber of profiles
Profiles9 records
Fresenius subsidiaries and ownership
Company hierarchySubsidiaries7 records
Fresenius funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fresenius M&A and investment
M&A and investmentM&A3 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fresenius
What does Fresenius do?
Fresenius is a global healthcare group selling pharmaceutical and medical products through Fresenius Kabi (biopharmaceuticals, biosimilars, clinical nutrition such as Fresubin and Pedismof, IV generics, infusion and transfusion systems including Aurora plasmapheresis and Cue/Lovo cell processing systems) to hospitals and healthcare providers worldwide. Through Fresenius Helios, it operates Europe's leading private hospital network with 140+ clinics across Germany (Helios Kliniken) and Spain (Quirónsalud), serving approximately 27 million patients annually.
Is Fresenius a public or private company?
Fresenius is a public company. It is classified as public and is currently operating.
When was Fresenius founded?
Fresenius was founded in 1912. It employs 5,001 to 10,000 people.
Where is Fresenius based?
Fresenius is headquartered in Bad Homburg Vor Der Höhe, Germany, in the Europe region.
How does Fresenius make money?
Three revenue lines are on record. Fresenius Kabi - Pharmaceutical and Medical Products are the primary driver. The others are fresenius Helios - Hospital Operations and strategic Investments.
Who are Fresenius's main competitors?
Broad incumbents on record are DaVita, Siemens Healthineers, Pfizer, Quirónsalud (Fresenius subsidiary) vs. peer hospital operators and HCA Healthcare. Direct peers are Baxter International, Sandoz Group, ICU Medical and B. Braun Melsungen. Formycon is listed as an emerging player.
Does Fresenius have an API?
No public API is recorded for Fresenius.
What industry is Fresenius in?
Fresenius's product category is Healthcare Services and Pharmaceutical Products. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 325412 and its SIC code is 2834.